Varying sensitivity to the sustanon 300 drug have: Enterococcus faecalis, Streptococcus pyogenes, pneumoniae and viridans, Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter, Mycoplasma hominis, Mycoplasma pneumoniae, Mycobacterium tuberculosis, Mycobacterium fortuitum, Ureaplasma urealyticum, Clostridium perfringens, Corynebacterium spp, Helicobacter pylori, Listeria. monocytogenes, Gardnerella vaginalis.
In most cases insensitive: Nocardia asteroides, anaerobic bacteria (e.g. Bacteroides spp, Peptococcus spp, Peptostreptococcus spp, Eubacter spp, Fusobacterium spp, Clostridium difficile…..). He acts on Treponema pallidum. Pharmacokinetics. After a single 60-minute time intravenous infusion of 200 mg ofloxacin mean maximum plasma concentration of 2.7 mcg / mL; 12 hours after the administration of the concentration equal to 0.3 mg / ml. The equilibrium concentrations are reached after administration cheryreh doses.
Mean peak and minimum equilibrium concentration achieved following intravenous administration of 200 mg of ofloxacin every 12 hours for 7 days, and are 2.9 and 0.5 ug / ml, respectively.
Ofloxacin penetrates widely in many body tissues and fluids, including saliva, bronchial secretions, bile, cerebrospinal fluid and tear, pus, lung, prostate and skin. Sustanon 300is partially exposed (5%) is metabolized in the liver. Plasma protein binding is 20 – 25%. The half-life is 6-7 hours ofloxacin. Up to 80% of ingested drug is excreted by the kidneys in an unmodified form, a small part of the active substances are also excreted in the feces. With hemodialysis removes 10 – 30% of the formulation.
In patients with impaired renal function (creatinine clearance of 50 mL or less) increases the half-life of ofloxacin.
respiratory tract infections (bronchitis, pneumonia), upper respiratory tract (sinusitis, pharyngitis, otitis media, laryngitis), skin, soft tissues, bones, joints, infectious and inflammatory diseases of the abdominal cavity and biliary tract (with the exception of bacterial enteritis) , the kidneys (pyelonephritis), urinary tract (cystitis, urethritis), pelvic organs (endometritis, salpingitis, oophoritis, cervicitis, Options, prostatitis), genitals (coleitis, orchitis, epididymitis), gonorrhea, chlamydia; septicemia, meningitis; prevention of infections in patients with impaired immune status (including neutropenia).
- Hypersensitivity or intolerance to ofloxacin and other fluoroquinolone derivatives;
- deficiency of glucose-6-phosphate dehydrogenase;
- epilepsy (including history);
- CNS reduced seizure threshold (after traumatic brain injury, stroke, inflammatory diseases of the brain).
- pregnancy, lactation;
- childhood and adolescence (18 years) has not yet completed skeletal growth
Caution should be exercised when administering the drug to patients with cerebral atherosclerosis, ischemic attack (a history of), organic lesions of the central nervous system, chronic renal failure.
Dosing and Administration
Intravenously. Doses are selected individually depending on the location and severity of the infection and the sensitivity of micro-organisms, the general condition of the patient, and liver and kidney function.
Intravenous drip begins with a single dose of 200 mg, administered slowly over 30-60 min. While improving the condition of the patient is transferred to oral administration of the same daily dose.
Urinary tract infections – 100 mg of 1 – 2 times a day, kidney infections and genital – 100 mg 2 times a day up to 200 mg two times a day, respiratory tract infection and upper respiratory tract, skin and soft tissue infections, bone and joint infections, abdominal infection, septic infections – 200 mg 2 times a day. If necessary, the dose was increased to 400 mg 2 times a day.
For the prevention of infections in patients with a severely reduced immunity – 400 – 600 mg / day.
If necessary / drip – 200 mg of 5% glucose solution. infusion duration – 30 min. Only fresh solution should be used.
In patients with impaired renal function (when creatinine clearance (CC) 50 – 20 ml / min), the single dose should be 50% of the average doses for the multiplicity of 2 times a day, or a full single dose is administered 1 time per day. When CC less than 20 ml / min, single dose – 200 mg, and then – 100 mg a day every other day.
In hemodialysis and peritoneal dialysis – 100 mg every 24 hours maximum daily dose of liver failure -. 400 mg / day.
Central nervous system: headache, convulsions, numbness and paresthesias of extremities, dizziness, depression, intense dreams, “nightmarish” dream, agitation, lack of movement, tremor; psychotic reactions, anxiety, phobias, confusion, hallucinations, increased intracranial sustanon 300 pressure;
From the sensory organs: impaired color vision, double vision, taste disturbance, -obonyaniya, hearing and balance;
From the digestive system: gastralgia, anorexia, nausea, vomiting, diarrhea, flatulence, abdominal pain, increased activity of “liver” transaminases, hyperbilirubinemia, cholestatic jaundice, pseudomembranous enterocolitis; From the musculoskeletal system: tendinitis, myalgia, arthralgia, tenosynovitis, tendon rupture;
Cardio-vascular system: tachycardia, decreased blood pressure (with on / in the introduction, with a sharp decrease in blood pressure introduction is stopped), vasculitis, collapse;
From the urinary system: acute interstitial nephritis, renal dysfunction, hypercreatininemia, elevated levels of urea; From the side of hematopoiesis: leukopenia, agranulocytosis, anemia, thrombocytopenia, pancytopenia, hemolytic and aplastic anemia;
For the skin: petechial hemorrhages (petechiae), hemorrhagic bullous dermatitis, papular rash with crusted showing vascular involvement (vasculitis);
Allergic reactions: skin rash, pruritus, urticaria, hypersensitivity pneumonitis, allergic nephritis, eosinophilia, fever, angioedema, bronchoconstriction; erythema multiforme exudative (including Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell’s syndrome), photosensitivity, anaphylactic shock;
Other: goiter, superinfection, vaginitis, hypoglycemia (in patients with diabetes); Local reactions: pain, redness at the injection site, thrombophlebitis (with on / in the introduction).
Symptoms: dizziness, confusion, lethargy, disorientation, drowsiness, and vomiting.
Treatment: gastric lavage, symptomatic therapy.
Effects on ability to drive vehicles and management mechanisms
In the period of treatment should refrain from driving motor vehicles and activities potentially hazardous activities that require high concentration and speed of psychomotor reactions
The interaction with other drugs
suitable for infusion solutions: an isotonic sodium chloride solution, Ringer’s solution, 5% fructose solution, 5% dextrose solution. Do not mix with heparin (risk of precipitation).
Decreases theophylline clearance by 25% (while the application should reduce the theophylline dose).
Cimetidine, furosemide, methotrexate, and drugs that block tubular secretion – ofloxacin increase the concentration in plasma.
Increases concentration of glibenclamide in plasma.
When concomitantly with vitamin K antagonists is necessary to control blood coagulation.
In the appointment of a non-steroidal anti-inflammatory drugs, derivatives of nitroimidazole and methylxanthines increases the risk of neurotoxic effects.
When concomitant administration with corticosteroids increases the risk of tendon rupture, particularly in elderly people.
In the appointment of agents, alkalizing urine (carbonic anhydrase inhibitors, citrate, sodium bicarbonate), increases the risk of crystalluria and nephrotoxic effects.
is not the drug of choice for pneumonia caused by pneumococcus. Not indicated sustanon 300 in the treatment of acute tonsillitis.
Not recommended for more than 2 months, exposed to sunlight, exposure to UV rays (mercury-quartz lamp, solarium).
In case of any side effects on the central nervous system, allergic reactions, pseudomembranous colitis requires removal of the drug. If pseudomembranous colitis, confirmed by colonoscopy and / or histologically demonstrated oral administration of vancomycin and metronidazole.
Rarely tendinitis can lead to tendon rupture (predominantly Achilles tendon), particularly in elderly patients. In the event of signs of tendonitis treatment should be discontinued immediately produce immobilization of the Achilles tendon and consult a podiatrist.
During the period of treatment can not use ethanol.
In applying the drug to women is not recommended to use tampons due to the increased risk of developing thrush.
The treatment possible worsening of myasthenia gravis, frequent attacks of porphyria in predisposed patients.